TCI Wealth Advisors Inc. Makes New Investment in Cencora, Inc. (NYSE:COR)

TCI Wealth Advisors Inc. acquired a new stake in Cencora, Inc. (NYSE:COR) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,358 shares of the company’s stock, valued at approximately $330,000.

A number of other large investors have also recently bought and sold shares of the business. Rise Advisors LLC acquired a new position in Cencora in the 1st quarter valued at about $25,000. Legacy Bridge LLC acquired a new stake in shares of Cencora during the first quarter worth $27,000. WASHINGTON TRUST Co purchased a new position in Cencora in the 1st quarter valued at $32,000. Hanson & Doremus Investment Management acquired a new position in Cencora in the 1st quarter valued at $33,000. Finally, OFI Invest Asset Management purchased a new position in Cencora during the 1st quarter worth $33,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Cencora news, EVP Gina Clark sold 27,093 shares of the company’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $216.07, for a total transaction of $5,853,984.51. Following the completion of the sale, the executive vice president now directly owns 15,158 shares in the company, valued at $3,275,189.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the transaction, the insider now owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The disclosure for this sale can be found here. Insiders sold 1,956,675 shares of company stock worth $422,352,056 in the last 90 days. 15.80% of the stock is owned by company insiders.

Cencora Trading Up 0.3 %

Shares of Cencora stock traded up $0.60 during mid-day trading on Friday, hitting $222.60. 791,079 shares of the stock were exchanged, compared to its average volume of 1,453,087. The stock has a market capitalization of $44.40 billion, a price-to-earnings ratio of 24.35, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The company has a 50-day simple moving average of $226.65 and a 200 day simple moving average of $229.62.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The firm had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. Cencora’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $3.50 earnings per share. Research analysts forecast that Cencora, Inc. will post 13.46 EPS for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s payout ratio is 22.32%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on COR shares. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Robert W. Baird increased their target price on Cencora from $280.00 to $285.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 9th. SVB Leerink reaffirmed an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Finally, Citigroup increased their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $236.10.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.